Fewer Than 1 in 4 Patients Stay on GLP-1 Drugs for Weight Loss After 12 Months

JAMA Network

The GLP-1 receptor agonist market is booming. Semaglutide, tirzepatide, and their competitors have become some of the most prescribed medications in the United States, driven by strong clinical trial results showing substantial weight loss. But a critical question lurks behind the prescribing surge: how many patients actually stick with these drugs?

The answer, according to a large new cohort study, is surprisingly few.

The persistence problem in numbers

In a study published in JAMA Network Open, researchers led by Luyu Xie at UT Southwestern examined treatment persistence among adults with overweight or obesity who did not have diabetes. The finding is stark: fewer than 1 in 4 patients remained on any GLP-1 receptor agonist (GLP-1RA) after 12 months.

That figure comes with an important nuance. The study also found that switching between different GLP-1RA agents was common. Patients were not simply starting a medication and then stopping all treatment. Many were moving from one agent to another, suggesting a pattern of active therapy management rather than straightforward medication abandonment.

Why patients switch and stop

The GLP-1RA class has expanded rapidly in recent years, with new formulations, dosing schedules, and combination products entering the market. This proliferation of options creates natural switching opportunities. A patient who experiences intolerable nausea on one agent might try another. Someone whose insurance formulary changes might switch to a covered alternative. A patient who started on a diabetes-approved formulation off-label for weight loss might transition to a weight-management-specific product as those became available.

Supply shortages, which plagued several GLP-1 drugs during their rapid adoption phase, also forced involuntary switching. When a patient's pharmacy cannot fill their prescription, they either switch agents, switch pharmacies, or go without.

The study's design, drawing from a large cohort of real-world patients, captures all of these dynamics in aggregate. It cannot isolate the reasons behind individual switches or discontinuations, but the overall pattern reveals a treatment landscape far messier than clinical trial retention rates might suggest.

What this means for patients and physicians

For patients, the low persistence rate raises practical concerns. GLP-1 drugs produce weight loss only while being taken. Multiple studies have shown that discontinuation leads to significant weight regain, often within months. If three-quarters of patients are off medication within a year, the population-level weight loss benefit may be substantially smaller than clinical trials predict.

For physicians, the switching pattern has implications for how they counsel patients and manage expectations. Starting a GLP-1RA is not a one-and-done decision; it is the beginning of an ongoing management process that may involve trying multiple agents, adjusting doses, and navigating insurance and supply barriers.

The framing matters too. A patient who switches from semaglutide to tirzepatide and maintains their weight loss is in a very different situation than one who stops all treatment. The study's finding that switching was common suggests that at least some patients classified as "non-persistent" on a specific drug were actually still engaged with GLP-1 therapy, just on a different agent.

The limits of what this study shows

Several important limitations constrain interpretation. The study did not report why patients discontinued or switched, leaving the relative contributions of side effects, cost, supply issues, patient choice, and clinical decision-making unknown. It focused on adults without diabetes, so the findings may not apply to the diabetic population, where GLP-1RAs have a longer track record and different insurance coverage patterns.

The study period matters too. The GLP-1 market has evolved rapidly, with new formulations and improved supply chains. Persistence patterns observed during earlier periods of shortage and limited options may not reflect current or future dynamics.

Crucially, the study does not report clinical outcomes. We do not know whether the patients who discontinued experienced weight regain, maintained behavioral changes initiated during treatment, or had other reasons for stopping that made discontinuation clinically appropriate.

A reality check for the GLP-1 era

The enthusiasm surrounding GLP-1 drugs for weight management is grounded in strong efficacy data from clinical trials, where patients receive medication for free, are closely monitored, and are motivated to adhere. Real-world persistence tells a different story: one of frequent switching, high discontinuation, and a treatment journey that looks nothing like a controlled trial protocol.

None of this means GLP-1 drugs do not work. They clearly do, for patients who take them. The challenge, as this study highlights, is keeping patients on them long enough to sustain the benefit. Solving that challenge will likely require addressing the full spectrum of barriers, from side effects and cost to supply reliability and the psychological difficulty of committing to indefinite medication use for a condition many patients do not experience as a disease.